Moreover, Schwann cell-targeted expression of Cx32 driven by a myelin-specific promoter can prevent or even reverse the demyelination and axonal degeneration occurring in the CMT1X mouse model providing a long-lasting therapeutic benefit even after the onset of the neuropathy. This evidence concerns the gene GJB1 and neuropathy.